Objective To investigate the clinical efficacy of Jinlong Gejie Pingchuan Capsule (for relieving asthma) in the treatment of stable-stage chronic obstructive pulmonary disease (COPD). Methods A total of 56 COPD patients were randomly divided into treatment group and control group, with 28 patients in each group. The two groups were given Jinlong Gejie Pingchuan Capsule and placebo, respectively, in addition to conventional treatment. The pulmonary function parameters, bone mineral density (BMD), body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index, score of COPD assessment test (CAT) questionnaire, and number of episodes of acute exacerbation within 1 year were observed before treatment and at 6 and 12 months after treatment. Results The pulmonary function parameters showed no significant differences between the two groups at 6 and 12 months after treatment (P>0.05). At 12 months after treatment, the treatment group showed a significant increase in BMD of the femoral neck (P<0.05), while the control group showed a significant reduction in BMD of the femoral neck (P<0.05). At 6 and 12 months after treatment, BODE index and the score on its subscale of six-minute walk distance showed significant differences between the two groups (P<0.05). The number of episodes of acute exacerbation within 1 year also showed a significant difference between the two groups (P<0.05). Conclusion In the patients with stable-stage COPD, Jinlong Gejie Pingchuan Capsule can effectively improve the pulmonary function, BODE index, and quality of life, and reduce the episodes of acute exacerbation within 1 year.